Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Implanted Sensor Provides Continuous Glucose Monitoring

By HospiMedica International staff writers
Posted on 28 Feb 2018
A novel continuous glucose monitoring (CGM) system measures interstitial fluid glucose levels in adults with diabetes for up to 180 days.

The Senseonics (Germantown, MD, USA) Eversense XL CGM system is designed to continuously monitor glucose levels below the skin surface around-the-clock, for the entire operating life of the sensor. More...
The system includes a small implantable sensor based on fluorescence technology, a removable, water-resistant, smart transmitter worn on the upper arm over the sensor insertion site, and an easy-to-use mobile app. The transmitter calculates current glucose values and determines if they are expected to exceed pre-set low and high targets.

The data and alerts are simultaneously sent to the smartphone app, which provides real-time tracking, intuitive displays to help identify trending patterns, and predictive alerts before reaching both low or high glucose levels. Recent study results in both Type 1 and Type 2 diabetes patients showed that the Eversense CGM was safe and highly accurate over the previous, 90-day sensor life, with more than 93% of glucose values within an acceptable range of reference values. The study was published on January 30, 2018, in Diabetes Technology and Therapeutics.

“When we introduced the Eversense System last year, we were providing the longest-wear sensor with up to 90-day wear for people with diabetes. Now, with the new Eversense XL System’s even longer sensor duration, patients can extend a single sensor wear over three seasons, inserting a new sensor in the Fall which will continue through the Winter, to be replaced in Spring,” said Tim Goodnow, CEO and President of Senseonics. “As we continue to advance our product portfolio with extended long-term sensor capabilities, we are offering added convenience to support patients’ continuous glucose management.”

“We are all aware of the advantages of continuous glucose monitoring seen now in many studies, including improvements in glycemic control, quality of life, and reduction in hypoglycemia,” said Pratik Choudhary, MD, consultant in diabetes at King’s College London (United Kingdom). “The benefits have been linked with long-term usage, which for many requires changing sensors every week. Eversense now offers a unique option for people who want to use CGM long term, with a long-lasting sensor that has demonstrated accuracy.”

Related Links:
Senseonics


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.